ONO-8711 

ONO-8711 is a potent and selective competitive antagonist of EP1 receptor (K_i = 0.6 and 1.7 nM for human and mouse EP1 respectively). ONO-8711 effectively reduces tumor incidence and multiplicity in mouse models of colon, breast, and oral cancer^[1].

ONO-8711 (10 and 30 μM; 30 min) blocks the contractions induced by sulprostone in human pulmonary veins in a non-competitive manner^[2].
ONO-8711 inhibits PGE₂-induced increase in cytosolic Ca²⁺ concentration with IC₅₀s of 0.21 μM, 0.05 μM, and 0.22 μM for the mouse, human, and rat receptors, respectively^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ONO-8711 (400 or 800 p.p.m.; p.o.; for 20 weeks) suppresses cancer incidence and delays occurrence of breast tumors^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

440.00

C₂₂H₃₀ClNO₄S

216158-34-8

O=C(O)CCC/C=C\[C@H]1C(CC2)CCC2[C@@H]1CNS(=O)(C3=CC=C(Cl)C=C3C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Watanabe K, et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999 Oct 15;59(20):5093-6.  [Content Brief]

  [2]. Norel X, et al. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat. 2004 Oct;74(1-4):101-12.  [Content Brief]

  [3]. Kawamori T, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.  [Content Brief]